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we have produced a chimeric single-chainT cell receptor (TcR) that combines the 
specific antibody recognition function and TcWCD3 signaling properties within 
the same polypeptide chain. This hybrid molecule consisted of a single-chain 
antibody combining site that was connected over a short spacer to the 
transmembrane and cytoplasmic region of CD31;. When expressed on TcR- or 
TcRf T cell hybridomas it could mediate recognition of relevent target cells and 
subsequent production of lymphokines; i. e. it could functionally replace the 
TcR/CD3 complex. Therefore, the single-chain TcR model presented here 
represents an interesting and useful means for the creation of T cells with new 
specificities. 
1 Introduction 
TheT cell antigen receptor (TcR) is a multiprotein complex 
composed of at least six different transmembrane proteins. 
The TcR a and fi chains are expressed as covalently linked 
afi heterodimers which provide the antigen specificity for 
T cells. While these proteins have large extracellular 
domains, their cytoplasmic portions contain only a few 
amino acids. The a and fi chains are noncovalently asso- 
ciated with the invariant subunits CD3y, -6, -E, -5 andor -11 
to form TcWCD3 complexes [l]. These associated proteins 
have large intracellular domains and are thought to couple 
the process of antigen recognition to the signal transduction 
pathways of the Tcell [2, 31. We wanted to bypass this 
complexity by creating a chimeric molecule that would 
retain both signaling and recognition functions within one 
polypeptide chain to generate an easily manipulatable 
system, which would allow us to change the specificity of a 
T cell at will. 
Following several experiments which showed, that the 
intracellular portion of the CD3c chain would be sufficient 
to induce activating signals after cross-linking of their 
artificial extracellular domains [4-61 we constructed a 
hybrid molecule, which unified the signaling properties of 
the CD35 chain and the antigen-binding ability of an 
antibody. For this we used a single-chain (Fv) mAb form [7] 
derived from TR66, an mAb specific for human C D ~ E  [8], 
and grafted it onto a short polypeptide spacer (hinge) from 
the CD8a chain. This chimeric extracellular domain was 
then finally fused to the transmembrane and cytoplasmic 
region of CD3c to form the single-chain TCR ‘‘FvCD3%,: 
When the construct coding for the single-chain TcR was 
transfected into TcR- or TcR+ T cell hybridomas, the 
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expressed chimeric molecule was able to  mediate recogni- 
tion of relevant target cells resulting in the production of 
IL-2 and IL-3 by the transfectants. 
Since the antigen specificity of our model chimera can easily 
be changed by replacing its Fv domain by other Fv derived 
from any antibody, this system could be useful in creating 
T cells of any desired specificity, bypassing the necessity of 
MHC restriction. 
2 Materials and methods 
2.1 Construction of the chimeric FvCD3L; 
The vector pHPAPr-1-neo-FvCD31; was designed to 
express the chimeric FvCD3L construct under the control of 
the human fi-actin promoter and bears a selectable neomy- 
cin marker. For its construction we removed the unique 
EcoRI restriction site in the plasmid pHPAPr-1-neo [9] by 
digesting it with EcoRI, blunting its cohesive ends and 
religating it. The polymerase chain reaction (PCR) was used 
to amplify a cDNA segment encoding for the cytoplasmic 
und transmembrane region of the murine CD35 chain and 
42 amino acids of the hinge region of murine CD8a 
(oligonucleotide primers 5451,5452). As a template for this 
reaction we used the plasmid CDS5 [6]. The primers of this 
reaction contained a SalI and a HindIII restriction site so 
that the amplified PCR product could be cloned after 
digestion with SalI and HindIII into the SalI-Hind111 
opened pHfiAPr-1-neo(RI). The resulting plasmid was 
opened by SalI, blunted and recut with EcoRI to receive the 
EcoRI-digested PCR-amplified cDNA fragment coding for 
theVDJ heavy and VJ light chain region of the mAbTR66. 
As a template for this PCR amplification we used the 
plasmid FvCD3 Hy3 [lo] and the oligonucleotide primers 
5971 and 5979 with the latter containing an EcoRI cloning 
site. 
The sequences of the used oligonucleotide primers are: 
5 ’TCCTGTCGACAGTGGA ATTCACTACTACCAAG- 
CCAGTGCTGC3 ’ (5451); 5’ GCATAAGClTGCCAGA- 
AGACCCAAGAGCAGGG3‘ (5452) ; 5 ‘TATGAGAATT- 
S’ACTGCATGAGCTCGAGACAACACTGACTCTAA- 
ClTTCAGCTCCAGCITGGTCCCAGC3‘ (5971); and 
CCATGGGA3’ (5972). 
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2.2 Cell lines and monoclonal antibodies 
BW5147a-P- is a derivative of the AKR/J lymphoma 
BW5147 that fails to express theTcR a ,  p, y, 6 and Uq genes 
[6, 111.14.3d is a mouseT helper hybridoma (derived from 
the T cell clone V244 that recognizes a hemagglutinin 
peptide of influenza virus A/PR/8/34 (HlN1) in the context 
of MHC class I1 I-Ed [ 121. The B lymphoma A20 [ 131 was 
used as antigen presenting cell for this peptide and Jurkat, a 
human acute T cell leukemia line (ATCC CFU 8162) and 
GC13, a human T cell clone (kindly provided by Dr. A. 
Lanzavecchia) were used as stimulators in the functional 
assays. All cells were cultured in IMDM containing 10 YO 
fetal calf serum. 
For immunofluorescence and immunoprecipitations we 
used the following mAb: anti-FvCD3 (rat anti-FvCD3; 
Traunecker, unpublished data); 2Cl l  (hamster anti-mouse 
C D ~ E ,  [14]), F23.1 (anti-mouse TcR Vp8; [15]). 
2.3 Immunofluorescence 
Expression of cell surface proteins was assayed by indirect 
immunofluorescence. Cell suspensions of 1 x 105 viable 
cells were stained with 20 pg /d  of first-step mAb. After 
30 min of incubation the cells were washed and incubated 
with the second-step FITC-conjugated goat anti-rat Ig 
(Southern Biotechnologies) at 10 pg/ml. Stained cells were 
washed and fixed in 1 % formaldehyde prior to cytofluor- 
ometric analysis using a FACScan (Becton Dickinson). 
dehyde. When the APC A20 was used to present influenza 
virus hemagglutinin peptide, the A20 cells were irradiated 
(8000rad) before being used at 5 x 104 per assay with 
various amounts of peptide. 
In each instance the supernatants of the stimulation assays 
were collected 24 h after the start of the experiment and 
tested for their level of IL-2 and IL-3 [16, 171 on the 
IL-Zdependent cell line CTL.L [18] and the IL-3-depen- 
dent cell line DA-1 [19]. 
3 Results and discussion 
3.1 General strategy 
To investigate if the TCR/CD3 multiprotein complex could 
be replaced functionally by a single-chain chimeric poly- 
peptide, we designed a chimeric gene, which could direct 
the synthesis of a protein consisting of the cytoplasmic and 
transmembrane region of mouse CD3<, a 42-amino acid 
segment of mouse CD8a as extracellular hinge region and 
the antigen combining site of the mAb TR66 (Fig. 1B); 
TR66 is specific for the human C D ~ E  chain [8], which was 
already successfully modified to bispecific single-chain Fv 
molecules by Traunecker et al. [lo]. The final construction 
(Fig. 1A) was then transfected by protoplast fusion [20] 
into the T hybridomas BWa-p- (TcR-) and 14.3d (TcR+) 
and G418-resistant stable transfectants were isolated and 
analyzed for expression and function of the chimeric 
single-chain TcR. 
2.4 Biochemical characterization of cell surface proteins 3.2 Surface expression and protein characterization 
Viable cells (3 x lo7) were washed five times in washing 
buffer (PBS, 1 m~ MgC12, 0.1 mM CaC12) and then bioti- 
nylated for 30min at 4°C in Sulfo-NHS biotin (Pierce, 
0.5 m g / d  in washing buffer). After another five washes the 
biotinylated cells were lysed in lysis buffer containing 
150 m~ NaCl, 50 m~ Tris, 1 mM PMSF, 10 mM iodoace- 
tamide and 0.5 % NP40 or 1 YO digitonin. The lysate was 
precleared overnight with protein G-Sepharose (Pharma- 
cia) and the immunoprecipitation was performed for 2 h 
with 10 pg specific mAb followed by a 1-h incubation with 
protein G-Sepharose. The precipitate was washed four 
times in lysis buffer and then boiled in 40 pl of 
1.5 x Laemmli sample buffer prior to SDS-PAGE using 
12.5 YO or gradient gels.The proteins were transferred from 
the SDS-PAGE to nitrocellulose which was then blocked in 
PBS, 0.4% Tween-20 (PBS-T) containing 5 % nonfat dry 
milk. It was subsequently incubated for 1 h in PBS-T 
containing 0.08 pg/ml streptavidin-horseradish peroxidase 
conjugate (Southern Biotechnology). The blot was washed 
three times for 5 min in PBS-T before addition of the ECL 
chemoluminescence reagent (Amersham) and the nitrocel- 
lulose was exposed to an X-ray film (Kodak) for 30 s to 
3 min. 
2.5 Stimulation of T cell transfectants 
In each assay 5 x 10" responder cells were stimulated with 
different amounts of humanT cells,which were fixed before 
the experiment by a 30-s treatment with 0.05 YO glutaral- 
The immunofluorescence analysis (Fig. 2) shows that the 
parental hybridomas BWa-p- (Fig. 2A) and 14.3d 
(Fig. 2C) did not stain with the mAb anti-FvCD3, while the 
Figure 1. (A) A schematic representation of the chimeric FvCD3s 
construct.The FvCD3S cDNA is expressed under the control of the 
human f3-actin promoter (P f3-Actin). The plasmid further cames 
selectable neomycin and ampicillin resistance genes (neo, amp) 
and a polyadenylation site (PA) at the 3'end of the cDNA. The 
indicated restriction sites are EcoRI (E), SalI (S) and HindIII (H). 
Restriction sites in parentheses have been removed by blunt end 
cloning. (B) The predicted structure of the FvCD35 polypeptide. 
The FvCD3 portion consists of the heavy and light chain variable 
regions (VH,VL) of TR66 connected by a glycine linker (Gly) [lo]. 
This Fv domain is followed by amino acid residues 122 to 164 of the 
hinge region of CD8a (numbering according to [22]) and the 
transmembrane (TM) and cytoplasmic portion (CY) of the t chain 
from residue 28 to  164 (numbering according to [23]). 
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surface-labeled 14.3d transfectant with 1 % digitonin- 
containing lysis buffer, which preserves the TcR/CD3 asso- 
ciation. The digitonin lysate of the 14.3 transfectant was 
either used for precipitation with the anti FvCD3-mAb 
(Fig. 3, lanes 5 ,6 )  or with F23.1[15], and antibody specific 
for the VPS segment of the TcRP chain (Fig. 3, lanes 7,8). 
The SDS-PAGE-analysis under nonreducing conditions 
revealed, that the F23.1 precipitation pattern of the 
untransfected 14.3d and its transfectant were identical: the 
major protein was the TcRaf3 heterodimer while an addi- 
tional coprecipitated FvCD3S homodimer on the transfec- 
tant could not be detected (Fig. 3, lanes 5, 6). Vice versa 
the immunoprecipitation with anti-FvCD3 did not co- 
precipitate TcR polypeptides from the 14.3d-transfectant 
(Fig. 3, lane 7). 
This analysis of the 14.3d transfectant indicated, that the 
chimeric FvCD31; protein was expressed independently 
from endogenousTcR/CD3 proteins and that its major form 
was a homodimer. Therefore, the presence of the endogen- 
eous TcR/CD3 complexes of the 14.3d transfectants should 
not sterically hinder the function of the FvCD35 polypep- 
tide and vice versa. 
B 
Fluore~cenca intensity 
Figure 2. Flow cytometry of cells stained with antibodies specific 
for mouse CD3 (mAb 2Cl1, dotted lines), FvCD3C (dashed lines) 
and second-step fluorescein-conjugated antibody only FITC-goat 
anti-rat, solid lines). (A) shows the untransfected parental hybri- 
doma BWa-B-, while (B) shows the staining of the BWa-6- 
transfectant BW TF1. The cytofluometric analysis of the TcR+ 
hybridoma 14.3d and its transfectant 14.3d TF1 are shown in (C) 
and (D), respectively. 
transfectants of each hybridoma (Fig. 2B,C) showed a 
surface staining indicating that the FvCD3 determinant was 
expressed on their surface. In contrast to 14.3d and its 
transfectants (Fig. 2C,D), the BWa-P- transfectants 
(Fig. 2B) as well as the parental BWa-f3- (Fig. 2A) did not 
express endogenous TcR/CD3 complexes, as monitored 
with the mouse CD3~-specific mAb 2Cll [14]. 
Theoretically, several possible forms of chimeric single- 
chain TcR could be expressed on the surface of the 
transfectants: while the BWa-P- transfectants should 
express FvCD31; independently of endogenous TcR/CD3 
complexes, an association could appear in the 14.3 trans- 
fectants. FvCD31; could then associate with endogenous 
TcR/CD3 complexes on the cell surface by charge pairing of 
its CD31; transmembrane region [21]. Furthermore, this 
CD35 transmembrane region could potentially permit 
covalent disulfide linkage between the single-chain 
FvCD31; and endogenous wild-type CD31; chains, resulting 
in the formation of CD31;-FvCD31; heterodimers. To inves- 
tigate which of these was expressed on the surface of our 
transfectants, we biotinylated the cell surface of these cells, 
lysed them either in 0.5 % "40 or 1 % digitonin and used 
the lysates for immunoprecipitations. 
The SDS-PAGE analysis of the immunoprecipitations 
under reducing conditions, followed by a Western blot 
analysis (Fig. 3, lanes 1,2), showed that the FvCD31; 
protein had an apparent molecular weight of 60 OOO on the 
BW transfectant when the FvCD3-specific mAb was used 
for precipitation. When analyzed under nonreducing con- 
ditions the FvCD31; protein seemed to have a dimeric and 
to a lesser degree tetrameric form on the BWa-fk 
transfectant (Fig. 3, lane 4). 
Surprisingly we could only detect homodimers on the 
surface of the 14.3d transfectant (Fig. 3, lane 7) and no 
CD3L-FvCD31; heterodimers; these findings suggest that 
those kinds of heterodimers are either not transported to 
the cell surface or they are not formed at all. 
To detect the eventual associations between FvCD31; and 
endogenous TcR/CD3 components we lysed the biotin 
3.3 Functional tests of the FvCD3c chimera 
According to the experiments of Irving and Weiss [4] and 
Romeo and Seed [5] the presence of the intracellular 
portion of CD35 was sufficient to activate their transfec- 
tants when the extracellular domains of their chimeric 
proteins CDS1; or CD45 were cross-linked by either CD8- 
specific mAb or gpl2O.We wanted to extend these findings 
and test if our transfectants would be able to recognize 
antigen (human C D ~ E )  through their FvCD3 domain and if 
this was sufficient to activate the T cell transfectants. 
Figure 3. Biochemical analysis of cell surface proteins: BWa-P- 
(lanes 1, 3) and one of its transfectants BWTFl (lanes 2,4) as well 
as 14.3d (lanes 6, 8) and its transfectant 14.3dTFl (lanes 5, 7) were 
cell surface biotinylated, lysed in either 0.5 % "40- (lanes 1-4) or 
1 % digitonin- (lanes 5-8) containing lysis buffer.The lysates were 
used for immunoprecipitations with either FvCD3-specific mAb 
(lanes 1-4, 7, 8) or TCR-specific mAb F23.1 (lanes 5 ,6 ) .  
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GC 13 JURKAT 
PEPTIDE CONCENTRATION (FM) JURKAT 
As stimulators we used Jurkat (Fig. 4B, D), a human CD3+ 
T cell lymphoma and GC13 (Fig. 4A), a humanT cell clone 
(A. Lanzavecchia, unpublished data). Both stimulators 
were fixed before the functional assays in order to make 
sure, that they could not be a source of lymphokine 
production (data not shown). Fig. 4A and B shows the 
results of the stimulation of BWa-P- and two of the BW 
transfectants. While the untransfected parental hybridoma 
was apparently neither activated by the stimulator cells 
GC13 (Fig. 4A), nor Jurkat (Fig. 4B), the two transfectants 
produced IL-2 (Fig. 4A, B) and IL-3 (data not shown) in a 
manner which was dependent on the number of each of the 
two types of stimulator cells. Furthermore, this stimulation 
could be inhibited specifically by TR66 (data not shown), 
the CD3&-specific mAb [8] from which the FvCD3 domain 
of our chimeric TcR was derived. We tested eight BW 
transfectants in total and all showed similar stimulation 
patterns to those showed in Fig. 4. 
To compare the efficiency of IL-2 and IL-3 production after 
stimulation over the chimeric single-chain receptor with 
conventional MHC-restricted stimulation with endogenous 
TcR/CD3 complexes we set up the following experiments: 
14.3d and two of its FvCD35 transfectants were tested for 
IL-3 (Fig. 4C, D) and IL-2 (data not shown) production 
during stimulation with APC (NO) and different amounts 
of antigenic peptide (Fig. 4C) or fixed human CD3+ Jurkat 
cells (Fig. 4D), respectively. While every tested cell was 
stimulated in a similarly efficient way by peptide plus A20 
(Fig. 4C), only the transfectants were able to produce IL-3 
(Fig. 4D) and IL-2 (data not shown) during stimulation by 
fixed Jurkat cells. Both kinds of assay showed that the 
production of lymphokines was either dependent on pep- 
tide concentration or on the number of stimulator cells, and 
indicated that the additional anti-human CD3 specificity on 
the 14.3d transfectants is caused by the expression of the 
single-chain TcR. A comparison of the stimulation efficien- 
Figure 4. IL-2 (A, B) and IL-3 (C, D) pro- 
duction of BW and 14.3d cells transfected 
with the chimeric FvCD3C gene constructs 
after stimulation with the fixed human T cells 
GC 13 (A), Jurkat (B, D) or peptide antigen 
presented by A20 (C). The parental cell 
BWa-P- (open circles) and two transfected 
subclones BW TF1 (closed circles) and BW 
TF2 (closed squares) were incubated with the 
indicated numbers of GC 13 (A) and Jurkat 
(B); 14.3d (open circles) and two of its 
transfectants [14.3d TF1 (closed circles), 
14.3d TF2 (closed squares)] were stimulated 
either by antigen-presenting cell and different 
peptide concentrations (C) or the indicated 
numbers of fixed Jurkat cells (D). After 22 h 
the supernatants were assayed for their con- 
tent of IL-2 or IL-3 using IL-Zdependent 
CI'L.L or IL-3-dependent DA-1 cells. 
cies through endogeneous TcR (Fig. 4C) and FvCD35 
single-chain TcR (Fig. 4D) shows that both signaling ma- 
chineries seem to be similarly efficient in inducing lympho- 
kine production in the same cell. While the peptide antigen 
presented by A20 is recognized in an MHC-restricted way, 
the CD3 recognition through FvCD35 resembles an anti- 
body-antigen interaction where no restricting MHC is 
needed. 
4 Concluding remarks 
Here we have demonstrated that the biological activities of 
helper T cell hybridomas can be directed by a single 
polypeptide chain that is able to recognize antigen and to 
transduce activating signals into the cell, which result in the 
production of biologically active lymphokines, in manners 
indistinguishable from normal antigen-specific stimulation. 
The anti-human CD3 specificity used in our experiments 
can be easily exchanged with Fv, of other desired specifici- 
ties derived from any existing mAb. Therefore, the single- 
chain TcR model presented here represents an interesting 
and useful means for the creation of Tcells with every 
desired specificity at will. 
While our manuscript was under preparation Eshhar et al. 
published a similar study [24] with comparable results. 
Their findings and those of Moritz et al. (personal commu- 
nication) combined with ours suggest that the single-chain 
TcR technology is generally applicable. 
We would like to thank Drs. Peter Lane and Antonio Lanzavecchia 
for critical reading of the manuscript. 
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